Sofosbuvir/velpatasvir,
does it really help with Sustained virologic response 12 weeks after treatment across all chronic hepatitis C genotypes?
research showsSofosbuvir/velpatasvir is rated B because it achieves very high SVR12 rates after 12 weeks across chronic hepatitis C genotypes 1 through 6. ASTRAL-1 achieved 99% (618/624) in genotypes 1, 2, 4, 5, and 6, while ASTRAL-2 achieved 99% in genotype 2 and ASTRAL-3 achieved 95% in genotype 3. SVR12 is a validated endpoint used as virologic cure because later relapse is rare, but pivotal phase 3 trials were concentrated in Gilead sponsorship and some used single-arm or performance-goal comparisons. Decompensated cirrhosis, prior DAA failure, and retreatment may change ribavirin use, duration, or regimen choice, and cure does not create immunity against reinfection.
ads claimPromotion can turn the result into a 100% cure for every hepatitis C patient in 12 weeks, erasing differences in genotype, cirrhosis, prior therapy, and interactions. Success is very high but not 100%, and decompensated cirrhosis or prior DAA failure requires specialist regimen selection.
Useful facts when choosing a product
- The adult fixed-dose tablet contains sofosbuvir 400 mg and velpatasvir 100 mg and is taken once daily; 12 weeks is a common standard duration without cirrhosis or with compensated cirrhosis.
- Decompensated cirrhosis should not simply receive the identical monotherapy regimen; specialist treatment such as 12 weeks with ribavirin is selected according to authorization and guidance.
- Headache and fatigue are common. Acid-reducing agents and several inducing medicines can reduce velpatasvir exposure, so every prescription, nonprescription drug, and supplement requires interaction review.
- Severe bradycardia has been reported when amiodarone is combined with sofosbuvir-containing therapy, so coadministration is not recommended. Prior hepatitis B infection is assessed before treatment because reactivation can occur.
What the research actually shows
In ASTRAL-1, 618 of 624 participants with genotypes 1, 2, 4, 5, or 6 achieved SVR12. In ASTRAL-2, 12 weeks of sofosbuvir/velpatasvir produced higher SVR12 in genotype 2 than 12 weeks of sofosbuvir/ribavirin; in ASTRAL-3, the corresponding result in genotype 3 was 95% versus 80% with 24 weeks of sofosbuvir/ribavirin. In ASTRAL-4 decompensated cirrhosis, overall SVR12 was 83% with 12 weeks alone, 94% with 12 weeks plus ribavirin, and 86% with 24 weeks alone, with ribavirin particularly important for genotype 3. All belonged to the Gilead development program.
Why this is classified as B (79)
ASTRAL repeatedly achieved 95% to 99% SVR12 across genotypes 1 through 6 using a clinically validated cure endpoint. Concentrated Gilead sponsorship and some single-arm or performance-goal structures, together with corpus parity with glecaprevir/pibrentasvir B79, yield B with 79 points. Headache, fatigue, interactions, and cirrhosis-specific regimens are safety and scope issues.
Counterpoint. Reinfection remains possible after SVR12, and patients with prior cirrhosis may continue liver-cancer surveillance and liver care. Cirrhosis stage, prior DAA exposure, drug interactions, and hepatitis B status matter to treatment design.
Rejudgment record. New verdict — Gave high weight to 95% to 99% SVR12 across all genotypes in the ASTRAL program and to SVR12 as a validated cure endpoint, while accounting for concentrated Gilead sponsorship, some single-arm or performance-goal comparisons, and corpus parity with glecaprevir/pibrentasvir B79
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Twelve-week SVR12 across all chronic hepatitis C genotypes without cirrhosis or with compensated cirrhosis | B | ASTRAL-1, ASTRAL-2, and ASTRAL-3 repeatedly achieved 95% to 99%, with manufacturer sponsorship and some single-arm or performance-goal structures. |
| The identical 12-week monotherapy regimen in decompensated cirrhosis or after prior DAA failure | C | ASTRAL-4 showed differences by ribavirin use and genotype, and prior DAA failure requires a separate retreatment strategy. |
| Prevention of hepatitis C reinfection after achieving SVR12 | ? | No human prophylactic efficacy literature supports vaccine-like use, and SVR12 does not create immunity. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Feld JJ et al. ASTRAL-1 2015 | Multicenter double-blind placebo-controlled phase 3 trial with a prespecified performance comparison | 6 | Sponsored by Gilead Sciences | SVR12 twelve weeks after completing twelve weeks of treatment | 618 of 624 participants, or 99%, achieved SVR12. | Pivotal pangenotypic cure evidence |
| Foster GR et al. ASTRAL-2 and ASTRAL-3 2015 | Randomized open-label active-controlled phase 3 noninferiority and superiority trials | 552 | Sponsored by Gilead Sciences | SVR12 | Rates were 99% versus 94% in genotype 2 and 95% versus 80% in genotype 3, favoring sofosbuvir/velpatasvir over sofosbuvir/ribavirin comparators. | Direct active-comparator confirmation in genotypes 2 and 3 |
| Curry MP et al. ASTRAL-4 2015 | Randomized open-label phase 3 trial in decompensated cirrhosis | 267 | Sponsored by Gilead Sciences | SVR12 with 12 weeks alone, 12 weeks plus ribavirin, or 24 weeks alone | Overall SVR12 was 83%, 94%, and 86%; genotype 3 achieved 85% with ribavirin versus 50% with either monotherapy duration. | Conditional-scope evidence in advanced cirrhosis |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Sofosbuvir/velpatasvir x 12-week SVR12 across all chronic hepatitis C genotypes — Evidence Grade B·79. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/sofosbuvir-velpatasvir-pangenotypic-hepatitis-c-svr12/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.